PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-299.87%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is 4.14%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.
38.60%
D&A growth of 38.60% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
-743.87%
Deferred tax shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see potential advantage if actual tax outflows do not spike.
496.12%
SBC growth of 496.12% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or staff additions causing more equity grants.
-210.10%
Working capital is shrinking yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage if sales remain robust.
135.91%
AR growth of 135.91% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or more relaxed credit if revenue is not matching it.
-67.21%
Inventory shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a working capital edge if sales hold up.
-143.11%
AP shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.
-64.54%
Other WC usage shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage if top-line is stable or growing.
217.83%
A moderate rise while Drug Manufacturers - Specialty & Generic median is negative at -6.88%. Peter Lynch might see peers cleaning up intangible or one-time items more aggressively.
-1249.62%
Negative CFO growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
7.24%
CapEx growth of 7.24% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.
-878.89%
Acquisition spending declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would note reduced M&A risk if growth continues organically.
77.18%
Purchases growth of 77.18% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or new strategic positions driving the difference.
349.80%
Proceeds growth of 349.80% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question if expansions or certain maturities are driving this difference.
-2950.17%
We reduce “other investing” yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a potential advantage in preserving cash if top-line growth is not harmed.
75.41%
Investing flow of 75.41% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or deals prompting that difference.
-4.64%
Debt repayment yoy declines while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.
144.58%
Issuance growth of 144.58% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or acquisitions financed by new shares.
No Data
No Data available this quarter, please select a different quarter.